Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JOUD HAJJAR and AUNG NAING.
JOUD HAJJAR
Connection Strength
4.440
AUNG NAING
  1. Unlocking the Potential of Anti-TIGIT Therapy-Between Promise and Challenges. JAMA Oncol. 2023 11 01; 9(11):1503-1504.
    View in: PubMed
    Score: 0.925
  2. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021 03 12; 11(1):5847.
    View in: PubMed
    Score: 0.770
  3. Metformin: an old drug with new potential. Expert Opin Investig Drugs. 2013 Dec; 22(12):1511-7.
    View in: PubMed
    Score: 0.457
  4. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer. 2023 08; 11(8).
    View in: PubMed
    Score: 0.227
  5. Author response to Cunha et al. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.197
  6. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52.
    View in: PubMed
    Score: 0.195
  7. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.193
  8. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.189
  9. T-cell agonists in cancer immunotherapy. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.187
  10. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
    View in: PubMed
    Score: 0.180
  11. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.179
  12. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018 Oct; 130:108-120.
    View in: PubMed
    Score: 0.161
  13. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
    View in: PubMed
    Score: 0.153
  14. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
    View in: PubMed
    Score: 0.152
  15. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017 02; 35(1):59-67.
    View in: PubMed
    Score: 0.141
  16. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer. 2015; 3:51.
    View in: PubMed
    Score: 0.134
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.